Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices. PURPOSE: To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes. DATA SOURCES: English-language studies from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, indexed from inception through March 2015 (MEDLINE search updated through December 2015). STUDY SELECTION: Paired reviewers independently identified 179 trials and 25 observational studies of head-to-head monotherapy or metformin-based combinations. DATA EXTRACTION: Two reviewers independently assessed study quality and serially extracted data and graded the strength of evidence. DATA SYNTHESIS: Cardiovascular mortality was lower for metformin versus sulfonylureas; the evidence on all-cause mortality, cardiovascular morbidity, and microvascular complications was insufficient or of low strength. Reductions in hemoglobin A1c values were similar across monotherapies and metformin-based combinations, except that DPP-4 inhibitors had smaller effects. Body weight was reduced or maintained with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors and increased with sulfonylureas, thiazolidinediones, and insulin (between-group differences up to 5 kg). Hypoglycemia was more frequent with sulfonylureas. Gastrointestinal adverse events were highest with metformin and GLP-1 receptor agonists. Genital mycotic infections were increased with SGLT-2 inhibitors. LIMITATION: Most studies were short, with limited ability to assess rare safety and long-term clinical outcomes. CONCLUSION: The evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). On the basis of less evidence, results for add-on therapies to metformin were similar to those for monotherapies. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compounds that modulate NF-κB signalling, including metformin137,235–237, apigenin238, kaempferol238 and BAY 11–7082 (REF.118), have also been shown to decrease SASP production.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [236]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We evaluated the heterogeneity among the trials by using the I(2) statistic (11).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We generated summary treatment effects with the random-effects model estimated by using the DerSimonian and Laird method in settings of low heterogeneity (I(2) < 50%) (12) and the profile likelihood estimate in settings of high heterogeneity (I(2) ≥ 50%) (13).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Two independent reviewers assessed risk of bias in individual RCTs by using the criteria of Jadad and colleagues (9), as in our prior review (6).”
MethodDowns, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252 · cited 1×
“We used the Downs and Black tool for assessment of the risk of bias for the nonrandomized trials and observational studies (10).”
MethodEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“diet) on the relative benefits of metformin and sulfonylureas for the spectrum of long-term outcomes important in diabetes (32).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Research works printed but not linked: 1
- Wang CP, 2014, J Endocrinol Diabetes Obes, 2
Cited by
Items 301–400 of 733
Syarifuddin, S., Nasution, A., Dalimunthe, A., & Khairunnisa, K. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.140 · Cited by 22
“The use of metformin as first-line therapy was supported by findings from a large meta-analysis [23], [24].”
MethodJang, J., Sung, E., Song, I., Lee, T. J., & Kim, J. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000966 · Cited by 16
Chou, M.-Y., Huang, S., Liang, C., Peng, L., Lin, Y., Hsiao, F., & Chen, L. (2021) · Age and Ageing · doi:10.1093/ageing/afab183 · Cited by 16
Montvida, O., Shaw, J. E., Blonde, L., & Paul, S. K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13288 · Cited by 16
“Overweight 20 477 (23) 6567 (23) 669 (10) 4217 (20) 3130 (22) 35 060 (22)”
de Oliveira, G. L. A., Guerra, A. A., Godman, B., & Acúrcio, F. D. A. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1292852 · Cited by 16
Aspinall, S. L., Hanlon, J. T., Niznik, J. D., Springer, S. P., & Thorpe, C. T. (2017) · Innovation in Aging · doi:10.1093/geroni/igx031 · Cited by 15
“In addition, the degree of A1c lowering is not the same across all classes of antidiabetic drugs and varies with monotherapy versus combination therapy (Inzucchi et al., 2015; Maruthur et al., 2016; Qaseem, Barry, Humphrey, Forciea, 2017).”
BackgroundJanney, C. A., Greenberg, J. M., Moin, T., Kim, H. M., Holleman, R. G., Hughes, M. V., Damschroder, L. J., Richardson, C. R., Young, A. S., & Steinle, N. (2018) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2018.04.001 · Cited by 18
Metformin: still the sweet spot for CV protection in diabetes?
Rena, G., Mordi, I. R., & Lang, C. C. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.018 · Cited by 16
Li, Q., Ren, C., Yan, S., Wang, K., Hrynets, Y., Xiang, L., Xue, X., Betti, M., & Wu, L. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c07160 · Cited by 14
Insulin in Frail, Older People with Type 2 Diabetes—Low Threshold for Therapy
Abdelhafiz, A. H., Bisht, S., Kovacevic, I., Pennells, D., & Sinclair, A. J. (2022) · Diabetology · doi:10.3390/diabetology3020028 · Cited by 14
Chang, R., Tu, T.-Y., Hung, Y., Huang, J., Chou, M., & Wei, J. C. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101368 · Cited by 14
Meta-Analysis of Microarray Expression Studies on Metformin in Cancer Cell Lines
Schulten, H.-J., & Bakhashab, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133173 · Cited by 15
“In T2D patients, increased circulating levels of GDF15 are associated with higher cancer incidence [44].”
BackgroundInfluentialKotsis, V., Jordan, J., Stabouli, S., Antza, C., Micić, D., Jelaković, B., Schlaich, M. P., Nilsson, P. M., Kreutz, R. H., Mancia, G., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002279 · Cited by 15
Yang, Q., Wang, G., Fang, D., Gao, X., Yu, L., Wang, L., Wu, J., Zeng, M., & Luo, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113130 · Cited by 14
Disorders of the Endocrine System and of Metabolism
Schifter, M., McLean, M. P., & Sukumar, S. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch22 · Cited by 18
Dai, C., Wang, D., Tao, Q., Li, Z., Zhai, P., Wang, Y., Hou, M., Cheng, S., Qi, W., Zheng, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1267963 · Cited by 13
Tong, X., Song, X., Zhang, Y., & Zhao, Q. (2024) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2024.2380422 · Cited by 13
Management of Diabetic Wounds: Expert Panel Consensus Statement
Hsia, H. C., Eriksson, E. K., Gurtner, G. C., Veves, A., Hamdy, O., Margolis, D. J., Armstrong, D. G., Lavery, L. A., Grice, E., Schultz, G., et al. (2025) · Advances in Wound Care · doi:10.1177/21621918251366586 · Cited by 16
“(2 ) Introduce SGLT2 inhibitors or GLP-1RAs in people with CVD at HbA1c goal (independent of metformin) for cardio-vascular bene fi t, independent of baseline HbA1c or individualized HbA1c target.”
InfluentialVlacho, B., Mata‐Cases, M., Mundet, X., Callol, J.-A. V. I., Real, J., Farré, M., Cos, X., Khunti, K., Mauricio, D., & Franch‐Nadal, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.708372 · Cited by 14
Oral Antidiabetics and Sleep Among Type 2 Diabetes Patients: Data From the UK Biobank
Xue, P., Wu, J., Tang, X., Tan, X. W., & Benedict, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.763138 · Cited by 15
Farhadi‐Azar, M., Ghahremani, M., Mahboobifard, F., Noroozzadeh, M., Yaghmaei, P., & Tehrani, F. R. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.05.003 · Cited by 14
“[13] Maruthur NM, Tseng E, Hutfless S, Wilson LM, SuarezCuervo C, Berger Z, et al.”
BackgroundSun, Q. L., Jia, H., Cheng, S., Wang, Y., & Wang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010343 · Cited by 15
Goldenberg, R. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.10.016 · Cited by 15
Monitoring Patients on Metformin: Recent Changes and Rationales
Wooley, A. C., & Kerr, J. L. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122517747295 · Cited by 14
Gas phase basicity of biguanides – Comparison of the equilibrium and the kinetic methods
Glasovac, Z., Eckert‐Maksić, M., Kaljurand, I., Saame, J., & Leito, I. (2018) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2018.10.010 · Cited by 13
High concurrent use of sulfonylureas and antimicrobials with drug interactions causing hypoglycemia
Pilla, S. J., Pitts, S. I., & Maruthur, N. M. (2022) · Journal of Patient Safety · doi:10.1097/pts.0000000000000739 · Cited by 12
“The clearance of thiazolidinediones, meglitinides, and the dipeptidyl peptidase-4 inhibitor saxagliptin is reduced by some antimicrobials, although these diabetes medications are less likely to cause hypoglycemia than sulfonylureas and are used less frequently.(16,17,33) Metformin, glucagon-like peptide 1 (GLP-1) rece…”
BackgroundSelf-citationFramework of Guidelines for Management of CKD in Asia
Pollock, C. A., Moon, J., Ha, L. P. N., Gojaseni, P., Ching, C. H., Gomez, L., Chan, T. M., Wu, M., Yeo, S. C., Nugroho, P., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.010 · Cited by 15
Yazidi, M., Kamoun, E., Oueslati, I., & Chihaoui, M. (2024) · Korean Journal of Family Medicine · doi:10.4082/kjfm.24.0090 · Cited by 12
Xu, L., Wu, Y., Li, J., Ding, Y., Chow, J., Li, L., Liu, H., Wang, Z., Gong, T., Li, Y., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088687 · Cited by 12
Biocatalyzed synthesis of antidiabetic drugs: A review
Alcántara, C., & Alcántara, A. R. (2017) · Biocatalysis and Biotransformation · doi:10.1080/10242422.2017.1323887 · Cited by 14
“The first class is represented by metformin, the first-line medication for the treatment of Type 2DM (Maruthur et al. 2016; Wise 2016), which is synthetized only by classical chemical methods, so that we will mention the other two classes, glitazones and glitazars.”
BackgroundChen, Y., An, X., Wang, Z., Guan, S., An, H., Huang, Q., Zhang, H., Liang, L., Huang, B., Wang, H., et al. (2021) · Aging · doi:10.18632/aging.202759 · Cited by 12
Nightmare and Abnormal Dreams: Rare Side Effects of Metformin?
Yanto, T. A., Huang, I., Kosasih, F. N., & Lugito, N. P. H. (2018) · Case Reports in Endocrinology · doi:10.1155/2018/7809305 · Cited by 12
Ruiz‐García, A., Arranz-Martínez, E., Merchante, I. M., Fuster, V. P., Tamarit, J. J., Trias, F., Pintó, X., & Ascaso, J. F. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.006 · Cited by 14
Neumiller, J. J., & Umpierrez, G. E. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0030 · Cited by 12
“Metformin is preferred as a first-line agent because of its demonstrated efficacy, safety, low cost, and possible benefits in reducing the risks of cardiovascular events and death (6,7).”
BackgroundYi, L., Zhang, H., Zhang, J., You, X., Ning, Z., Yu, J., Qian, L., & Miao, L. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.668 · Cited by 12
Ali, A., Unnikannan, H., Shafarin, J., Bajbouj, K., Taneera, J., Muhammad, J. S., Hasan, H. A., Salehi, A. A., Awadallah, S. M., & Hamad, M. A. (2022) · Endocrine · doi:10.1007/s12020-022-03022-x · Cited by 12
Kamali, F., Rajaei, G. E., Mohajeri, S., Shamel, A., & Khodadadi-Moghaddam, M. (2022) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2022.109527 · Cited by 12
Tseng, Y., Steinberg, G., Fox, K. P., Armstrong, J., & Mandl, K. D. (2017) · Diabetes Care · doi:10.2337/dc17-0213 · Cited by 12
An In Ovo Model for Testing Insulin-mimetic Compounds
Haselgrübler, R., Stübl, F., Stadlbauer, V., Lanzerstorfer, P., & Weghuber, J. (2018) · Journal of Visualized Experiments · doi:10.3791/57237-v · Cited by 12
Hsu, C., Abbood, M. A., Abbood, N. K., Al-Athari, A. J. H., Shather, A. H., Kareem, A. T., Ahmed, H. H., & Yadav, A. (2023) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2023.2267718 · Cited by 11
Zhang, Y., Wang, A., Zhao, W., Qin, J., Zhang, Y., Liu, B., Yao, C., Long, J., Yuan, M., & Yan, D. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2450871 · Cited by 15
Bredehorst, M., González‐González, A. I., Schürmann, L., Firmansyah, D., Muth, C., Haasenritter, J., van der Wardt, V., & Puzhko, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1494234 · Cited by 13
Nanoliposome-based drug delivery systems for the treatment of diabetes mellitus: a review
Umar, M., Sherazi, T. A., Talha, M., Ramadan, M. F., Ahmed, A. E., Taha, R., & Naqvi, S. A. R. (2025) · RSC Advances · doi:10.1039/d5ra07152f · Cited by 11
Old Drug, New Science: Metformin and the Future of Pharmaceutics
Caturano, A., Nilo, D., Nilo, R., Sircana, M. C., Erul, E., Zielińska, K., Russo, V., Santonastaso, E., & Sasso, F. C. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010077 · Cited by 13
“As its role as a foundational therapy became established, metformin was co-formulated with sulfonylureas, thiazolidinediones, DPP-4 inhibitors, and later SGLT2 inhibitors to simplify regimens and enhance adherence [23].”
Pawaskar, M. D., Bilir, S. P., KOWAL, S. L., González, C. D., Rajpathak, S. N., & Davies, G. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13618 · Cited by 11
Metformin Indications, Dosage, Adverse Reactions, and Contraindications
Stoica, R. A., Ștefan, D. S., Rizzo, M., Suceveanu, A., Suceveanu, A. P., Serafinceanu, C., & Stoian, A. P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88675 · Cited by 17
Liu, S., Xu, L., Ma, J., Huang, R., Lin, T., Zhuo, L., Liang, H., Li, S., Li, R., Zhang, L., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12757 · Cited by 11
Diav‐Citrin, O., Steinmetz-Shoob, S., Shechtman, S., & Ornoy, A. (2018) · Reproductive Toxicology · doi:10.1016/j.reprotox.2018.05.007 · Cited by 12
Mok, S. W. F., Wu, J., Niu, Y., Coghi, P. S., Wu, Y., Sin, W. M., Ng, S. I., Gordillo-Martínez, F., Gao, J., Law, B. Y. K., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00710 · Cited by 11
“…can interact with LKB1, the upstream kinases of AMPK (Fryer et al., 2002; Shaw et al., 2005) or inhibit complex I of the mitochondrial respiratory chain (Doran and Halestrap, 2000) to reduce blood glucose level which serve as a first-line therapy for type II diabetes (Maruthur et al., 2016).”
BackgroundCurrent Approaches in Diabetes Treatment and Other Strategies to Reach Normoglycemia
Sirhan, W., & Piran, R. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200716113813 · Cited by 13
Weng, L., Chen, T., Huang, L., Lai, D., Kang, N., Fu, Y., & Weng, C. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13971 · Cited by 11
Das, A. K., Shah, S., Singh, S. K., Juneja, A., Mishra, N. K., Dasgupta, A., Deka, N., Abhyankar, M., & Revankar, S. Y. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211030513 · Cited by 11
Hosio, M., Urpilainen, E., Hautakoski, A., Marttila, M., Arffman, M., Sund, R., Ahtikoski, A. M., Puistola, U., Läärä, E., Karihtala, P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88488-x · Cited by 10
Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
Sečník, J., Xu, H., Schwertner, E., Hammar, N., Alvarsson, M., Winblad, B., Eriksdotter, M., Ptacek, S. G., & Religa, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215337 · Cited by 11
Jiang, L., Hu, X., & Cai, L. (2022) · Molecules · doi:10.3390/molecules27113472 · Cited by 10
“Metformin (MET, Figure 1b), the most widely prescribed antihyperglycemic agent, is recommended by guidelines of many countries and international organizations as a first-line monotherapy for type 2 diabetes mellitus worldwide [12].”
BackgroundXiong, X., Chen, Y., Yuan, R., Qiu, G., Weir, M. D., Xu, H. H. K., Liu, J., Ruan, J., Chang, X., & Qu, S. (2022) · Journal of Bionic Engineering · doi:10.1007/s42235-022-00241-w · Cited by 10
“Metformin was an insulin-sensitizing drug widely used for diabetes treatment due to its excellent performance such as being safe, non-toxic, and well-tolerated [49].”
BackgroundXu, C., He, L., Zhang, J., Xu, L., Dong, J., & Liao, L. (2022) · Metabolites · doi:10.3390/metabo12100979 · Cited by 11
“Similarly, the beneficial effect of SGLT2i on the modulation of blood pressure was also confirmed by our meta-analysis, which was consistent with the previous reports [71,72].”
ResultRutledge, C. A., Lagranha, C. J., Chiba, T., Redding, K., Stolz, D. B., Goetzman, E. S., Sims‐Lucas, S., & Kaufman, B. A. (2023) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2023.100034 · Cited by 13
Therapy of Type 2 diabetes: more gliflozines and less metformin?
Verdecchia, P., Murdolo, G., Coiro, S., Santucci, A., Notaristefano, F., Angeli, F., & Cavallini, C. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad098 · Cited by 10
“7,8 Essentially on the basis of the results of the UKPDS study (both in terms of the initial randomized study and in terms of a 10-year ‘free’ follow-up), the joint guidelines of the American Diabetes Association/European Association for the study of Diabetes (ADA/EASD) recommend metformin as a…”
BackgroundYazidi, M., Kamoun, E., Taieb, S. H., Rejeb, O., Mahjoub, S., Maryam, S., Feki, M., Oueslati, I., & Chihaoui, M. (2023) · Chronic Illness · doi:10.1177/17423953231184220 · Cited by 10
Clinical Characterization of Data-Driven Diabetes Clusters of Pediatric Type 2 Diabetes
Abbasi, M., Tosur, M., Astudillo, M., REFAEY, A. K., Sabharwal, A., & REDONDO, M. J. (2023) · Pediatric Diabetes · doi:10.1155/2023/6955723 · Cited by 10
Feng, Q., Ruan, X., Lu, M. M., Bu, S., & Zhang, Y. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06321-9 · Cited by 11
“Several clinical trials demonstrated that metformin can improve cardiovascular outcomes in type 2 diabetic patients, independent of its hypoglycemic effects [15, 16].”
Guo, L., Wang, L.-W., Tian, D.-Z., Xu, F.-M., Huang, W. M., Wu, X., Zhu, W., Chen, J., Zheng, X., Zhou, H., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01638-y · Cited by 10
The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
Dhindsa, D. S., Sandesara, P. B., & Shapiro, M. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00160 · Cited by 10
Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2
Guisasola, F. Á., Orozco‐Beltrán, D., Cuenca, A. M. C., Quintero, M. A. R., Angullo-Martínez, E., Lachica, L. Á., Millán, C. O., Caride-Miana, E., Navarro-Pérez, J., Pérez, J. S., et al. (2019) · Atención Primaria · doi:10.1016/j.aprim.2019.05.014 · Cited by 19
Won, J. C. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_11 · Cited by 12
Wang, X., Wang, H., Yi, P., Baker, C. K., Casey, G., Xie, X., Luo, H., Cai, J., Fan, X., Soong, L., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110512 · Cited by 10
Hu, S., Su, X., Deng, X., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.701446 · Cited by 10
Jin, B.-Y., Lee, S., Kim, W., Park, J.-H., Cho, H., Moon, S., & Ahn, S. (2025) · Annals of Intensive Care · doi:10.1186/s13613-025-01490-8 · Cited by 9
Plant Heteropolysaccharides as Potential Anti-Diabetic Agents: A Review
He, D., & Cui, C. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47070533 · Cited by 9
“…managing blood glucose, they are associated with notable adverse effects, including abdominal pain, gastrointestinal disturbances (diarrhea/constipation), nausea, hypersensitivity reactions, weight fluctuations, and severe hypoglycemia, which severely affect the quality of life of patients [10–13].”
Chaudhary, N. K., Guragain, B., Chaudhary, A., & Chaudhary, S. K. (2021) · Chemical Papers · doi:10.1007/s11696-021-01535-9 · Cited by 9
“MF is a commonly used antidiabetic drug for the control of noninsulin-dependent type 2 diabetes mellitus [T2DM] (Maruthur et al. 2016).”
BackgroundKhalid, W., Arshad, M. S., Imran, M., Ahmad, R. S., Imran, A., Qaisrani, T. B., Asghar, Z., Husain, A., Anjum, F. M., & Suleria, H. A. R. (2021) · Food Science & Nutrition · doi:10.1002/fsn3.2476 · Cited by 12
RetractedBorozdina, N. A., Dyachenko, I. A., & Popkova, D. V. (2024) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162024040137 · Cited by 9
Wu, J., Yang, R., Yu, H., Qin, X., Wu, T., Wu, Y., & Hu, Y. (2023) · Nutrients · doi:10.3390/nu15143081 · Cited by 12
“Firstly, the medical records used in this study do not include detailed clinical information, such as hemoglobin levels [3,40].”
BackgroundMethodBioanalytical Methods for The Detection of Antidiabetic Drugs: A Review
Fachi, M. M., Leonart, L. P., Pontes, F. L. D., Vilhena, R. D. O., Cerqueira, L. B., & Pontarolo, R. (2017) · Bioanalysis · doi:10.4155/bio-2017-0182 · Cited by 9
Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human
Liu, L. Z., Ma, T., Zhou, J., Hu, Z. L., Zhang, X. J., Zhang, H. Z., Mi, Z., Liu, J., Li, L., Jiang, Y., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126857 · Cited by 9
Boichard, A., Richard, S. B., & Kurzrock, R. (2020) · Cancers · doi:10.3390/cancers12010166 · Cited by 9
“Combination therapy has been widely used for the prevention or treatment of diabetes [11], Alzheimer’s disease, or cardiovascular diseases [12,13], and has proven to be particularly effective for the treatment of HIV/AIDS as well as cancers such as Hodgkin lymphoma [14–16].”
MethodALOthman, Z. A., Alsheetan, K. M., Al‐Anazy, M. M., Locatelli, M., & Ali, I. (2021) · International Journal of Environmental Science and Technology · doi:10.1007/s13762-021-03218-0 · Cited by 9
Lee, K. A., Jin, H. Y., Kim, Y. J., Kim, S. S., Cho, E.-H., & Park, T. S. (2022) · Medicine · doi:10.1097/md.0000000000028823 · Cited by 9
“Compared with SU in a previous meta-analysis, metformin as a first-line monotherapy was beneficial in terms of HbA1c levels, weight gain, and cardiovascular mortality.([15]) On the other hand, patients with uncontrolled hyperglycemia associated with T2D can be effectively treated with SU.”
Chen, C., Ko, Y., Chen, C.-H., Hung, Y.-J., Wei, T.-E., Chang, T.-H., Ke, S.-S., Kuo, K. N., & Chen, C. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.01.026 · Cited by 9
Huang, H., & Yeh, J. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.032 · Cited by 9
Solanki, A., Kamrava, M. R., Posadas, E. M., Freedland, S. J., Ballas, L., Sandler, H. M., Merz, C. N. B., Atkins, K. M., & Nikolova, A. (2024) · Cancer · doi:10.1002/cncr.35285 · Cited by 8
Unveiling the Value of Meta-Analysis in Disease Prevention and Control: A Comprehensive Review
Ntais, C., & Talias, Μ. A. (2024) · Medicina · doi:10.3390/medicina60101629 · Cited by 10
“For example, guidelines for managing diabetes often rely on meta-analyses that evaluate the efficacy of different treatments in achieving glycemic control [52].”
BackgroundGu, S., Hu, X., Shi, L., Zhen, X., Sun, X., Huang, M., Gu, Y., & Dong, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237094 · Cited by 10
“This study showed that SUs had higher hypoglycemia risks than other drug classes, which is consistent with the previous studies [207,208].”
BackgroundResultInfluentialFlory, J., Ukena, J., & Floyd, J. S. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0633-y · Cited by 9
Improving Dissolution and Cytotoxicity by Forming Multidrug Crystals
Bian, X., Jiang, L., Zhou, J., Guan, X., Wang, J., Xiang, P., Pan, J., & Hu, X. (2020) · Molecules · doi:10.3390/molecules25061343 · Cited by 8
Metformin Ameliorates Neuronal Necroptosis after Intracerebral Hemorrhage by Activating AMPK
Lin, C., Yang, K., Zhang, G., & Yu, J. (2021) · Current Neurovascular Research · doi:10.2174/1567202618666210923150251 · Cited by 8
Metformin protects against cardiac and renal damage in diabetic cardiac arrest patients
Rutledge, C. A., Kaufman, B. A., Dezfulian, C., & Elmer, J. (2022) · Resuscitation · doi:10.1016/j.resuscitation.2022.03.017 · Cited by 8
Rodríguez-Rivera, N. S., Cuautle-Rodríguez, P., Castillo‐Nájera, F., & Molina-Güarneros, J. (2017) · Biomedical Reports · doi:10.3892/br.2017.921 · Cited by 10
Monotherapy in patients with type 2 diabetes mellitus
Rhee, S. Y., Kim, H. J., Ko, S., Hur, K. Y., Kim, N. H., Moon, M. K., Park, S.-O., Lee, B., Choi, K. M., & Kim, J. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.312 · Cited by 9
“In several subsequent observational studies and meta-analyses, there was evidence that metformin could be the drug of choice for initial treatment of diabetes patients compared to sulfonylurea, thiazolidinedione, and dipeptidyl peptidase 4 (DPP4) inhibitor, from the aspects of HbA1c reduction, side effects, weight gai…”
BackgroundDomecq, J. P., Prutsky, G. J., Elraiyah, T. A., Wang, Z., Mauck, K. F., Brito, J. P., Undavalli, C., Sundaresh, V., Prokop, L. J., Montori, V. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01269 · Cited by 8
Metformin dosage patterns in type 2 diabetes patients in a real-world setting in the United States
Mahabaleshwarkar, R., & DeSantis, A. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108531 · Cited by 8
Blonde, L., Patel, C. A., Wu, B., Chen, Y., Pericone, C. D., & Bookhart, B. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01549-x · Cited by 8
Metformin monotherapy for adults with type 2 diabetes mellitus
Gnesin, F., Thuesen, A. C. B., Kähler, L. K. A., Gluud, C. N., Madsbad, S., & Hemmingsen, B. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012906 · Cited by 11
Seferovic, M. D., Beamish, C. A., Mosser, R. E., Townsend, S. E., Pappan, K. L., Poitout, V., Aagaard, K. M., & GANNON, M. A. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00001.2018 · Cited by 8
“Dimethyl biguanide (metformin) is a first-line treatment for Type 2 diabetes, particularly in overweight individuals (51), affecting blood glucose reduction by inhibiting hepatic glucose generation and promoting adipose- and muscle-glucose uptake (3).”
BackgroundShinzaki, S., Sato, T., & Fukui, H. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-01983-y · Cited by 8
“Neither study provides detailed information on the diabetes control status [6], background environmental factors [7], or detailed clinical, biomarker-based, and endoscopic studies of IBD disease activity or severity.”
BackgroundZhang, B., Jia, Y., Yan, J., Zhou, J., Rustamova, N. A., Cao, J., & Huang, G. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501153 · Cited by 7
Gu, S., Hu, X., Zhen, X., Shi, L., Shao, H., Sun, X., Gu, Y., Huang, M., & Dong, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185435 · Cited by 10
“To our knowledge, only a few systematic reviews were found to compare several drug classes, but they were not targeted at Chinese patients, did not cover all available drugs, and only included English-language studies [339,340,345,349,351].”
BackgroundResultInfluentialCanagliflozin-induced adaptive metabolism in bone
Poudel, S. B., Chlebek, C., Ruff, R. R., He, Z., Xu, F., Yildirim, G., Hu, B., Jesus, C. L. D., Shinde, A. R., Nayak, V. V., et al. (2025) · Diabetes · doi:10.2337/db24-0955 · Cited by 7
Clinical Impact of Combination Therapy in Diabetic Neuropathy and Nephropathy
Kaur, H., Kaur, A., Prashar, P. K., Gautam, A., Sood, A., Singh, S. K., Gulati, M., Pandey, N. K., & Kumar, B. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.00603 · Cited by 7
Metadata
- Authors
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S.
- Affiliations
- MetroHealth (US)
- From The Johns Hopkins University School of Medicine; The Johns Hopkins University Bloomberg School of Public Health; and Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, and Center for Health Care Research and Policy, MetroHealth/Case Western Reserve University; MetroHealth Medical Center; and Case Western Reserve University, Cleveland, Ohio.
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-06-07
- Volume
- 164
- Issue
- 11
- Pages
- 740-751
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2340898396
- Cited by
- 682
- References
- 66
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 60 · 2023: 68 · 2022: 80 · 2021: 90 · 2020: 89 · 2019: 71 · 2018: 68 · 2017: 56 · 2016: 11
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- Agency for Healthcare Research and Quality (290-2012-00007-I)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, metformin, monotherapy, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular mortality, glycemic control, HbA1c, weight loss, hypoglycemia, gastrointestinal adverse effects, genital mycotic infections, first-line therapy
- MeSH terms
- Adult, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.